COVID-19 vaccination for hematopoietic stem cell transplant patients

The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...

How has the COVID-19 pandemic impacted patients with AML?

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the AML Hub spoke with Talati Chetasi, Moffitt Cancer Center,...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Positive topline results from a phase II trial of antroquinonol for patients with AML

On November 26, 2020, a press release on topline results from a phase II trial (NCT03823352) of antroquinonol in...

Germline mutations in patients with hematologic malignancies

Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...

FDA grants orphan drug designation to eprenetapopt for TP53-mutated AML

Very recently, eprenetapopt (APR-246), a small molecule that reactivates mutant and inactivated p53 protein, was granted orphan...

Is a TP53 mutation always a poor prognostic marker for transplantation in AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience...

SNDX-5613 shows encouraging overall response rate in relapsed/refractory acute leukemias

SNDX-5613, a potent, highly selective, oral inhibitor of the menin-mixed lineage leukemia (MLL) binding...

FDA approves extended indication of daunorubicin plus cytarabine to include pediatric patients with AML

On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication...

Augmented reduced-intensity allo-HSCT in patients with high-risk AML or MDS: Results of the FIGARO trial

Previously, older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)...

How cytogenetic risk impacts the outcome of allogeneic stem cell transplantation

Cytogenetic profile is a predictor of outcome in patients with acute myeloid leukemia (AML). It also helps with the...